Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
AUSTIN, Texas, May 22, 2012 /PRNewswire/ — Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer.
Prodigy partnered with eVenus Pharmaceutical Laboratories to develop a portfolio of oncology products. Irinotecan is the first of several ANDAs being developed through the partnership that will add consistent supply and exceptional value to the U.S. injectable market, which has experienced record levels of shortages in the last year.
Irinotecan is indicated for use in the treatment of cancer, primarily colon cancer. It’s used in the FOLFIRI chemotherapy regimen consisting of infusional 5-fluorouracil, leucovorin, and irinotecan. Irinotecan is available in 2ML (20 MG per ML) and 5ML (20 MG per ML).
“This launch represents an important milestone for Prodigy. Irinotecan is a drug that was on the FDA drug shortage list in the last year and is a great addition to our expanding generic drug pipeline. We could not be more excited about our partnership with eVenus to add consistent supply to the market,” states Jon Houssian, President of Prodigy Generics.
Prodigy Health Supplier Corporation (PHS) was established in 2001 and is based in Austin, Texas. Since inception PHS has been a consistent and dependable supplier in the bio-pharmaceutical industry and has grown into one of the leading suppliers of plasma derivatives and injectables in the United States.
eVenus Pharmaceutical Laboratories Inc., a wholly owned subsidiary of Jiangsu Hengrui Medicine Co, Ltd., was established in the United States in 2009. The company, located in Cranbury, New Jersey, is based on a development and manufacturing history that spans over 40 years.
SOURCE Prodigy Health Supplier Corporation